Clinical Trial: Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259889) titled 'Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors' on Nov. 14.

Brief Summary: This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.

Study Start Date: June 16

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors (Phase 1)

Intervention: DRUG: NK cell preparation

CEL001 injection

Recruitment Status: RECRUITING

Sponsor: Guangzhou Xiling Biotechnology C...